Last reviewed · How we verify
NCT04228406
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Phase 1 trial testing GST-HG161 in Solid Tumor in 62 participants. Status unknown.
30 September 2020
Quick facts
| Lead sponsor | Fujian Cosunter Pharmaceutical Co. Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 1 July 2019 |
| Primary completion | 30 September 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- GST-HG161 — full drug profile →
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
- C-Met Mutation-Related Tumors — all drugs for C-Met Mutation-Related Tumors →
Sponsor
Fujian Cosunter Pharmaceutical Co. Ltd — full company profile →
Who can join
18 and older, any sex, with Solid Tumor or C-Met Mutation-Related Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple administration, dose escalation, and expanded phase I trial
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04228406
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Other Fujian Cosunter Pharmaceutical Co. Ltd trials
Trials by the same sponsor.
- NCT05345964 — Phase I Study of GST-HG151 Tablets in Healthy Volunteers · Phase 1 · unknown
- NCT04868981 — Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets · Phase 1 · completed
- NCT04499443 — Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets · Phase 1 · unknown
- NCT04386915 — Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04228406 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cosunter Pharmaceutical Co. Ltd
- Last refreshed: 14 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04228406.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing